Nanomaterial Delivery Systems for mRNA Vaccines.
Vaccines (Basel)
; 9(1)2021 Jan 19.
Article
in English
| MEDLINE | ID: covidwho-1389566
ABSTRACT
The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Topics:
Vaccines
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
VACCINES9010065
Similar
MEDLINE
...
LILACS
LIS